In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China

被引：78

作者：

Wang, Xiaojuan ^{[1
]}

Zhang, Feifei ^{[1
]}

Zhao, Chunjiang ^{[1
]}

Wang, Zhanwei ^{[1
]}

Nichols, Wright W. ^{[2
]}

Testa, Raymond ^{[2
]}

Li, Henan ^{[1
]}

Chen, Hongbin ^{[1
]}

He, Wenqiang ^{[1
]}

Wang, Qi ^{[1
]}

Wang, Hui ^{[1
]}

机构：

[1] Peking Univ, Peoples Hosp, Dept Clin Lab, Beijing 100871, Peoples R China

[2] AstraZeneca Pharmaceut LP, Waltham, MA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 03期

关键词：

BETA-LACTAMASE INHIBITOR; KLEBSIELLA-PNEUMONIAE; KPC CARBAPENEMASES; NXL104; COMBINATION; ENTEROBACTERIACEAE;

D O I：

10.1128/AAC.02123-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ceftazidime-avibactam, aztreonam-avibactam, and comparators were tested by reference broth microdilution against 372 non-repetitive Gram-negative bacilli (346 unselected plus 26 selected meropenem-nonsusceptible Enterobacteriaceae isolates) collected from 11 teaching hospitals in China in 2011 and 2012. Meropenem-nonsusceptible isolates produced extended-spectrum beta-lactamases (ESBLs; e. g., CTX-M-14/3), AmpCs (e. g., CMY-2), and/or carbapenemases (e. g., KPC-2 and NDM-1). Avibactam potentiated the activity of ceftazidime against organisms with combinations of ESBLs, AmpCs, and KPC-2. Aztreonam-avibactam was active against all beta-lactamase producers (including producers of NDM-1 and IMP-4/8) except bla(OXA)-containing Acinetobacter baumannii and some Pseudomonas aeruginosa isolates.

引用

页码：1774 / 1778

页数：5

共 19 条

[1] In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Aktas, Z.
Kayacan, C.
Oncul, O.
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (01) : 86 - 89
[2] Clinical and Laboratory Standards Institute, 2012, M7A9 CLIN LAB STAND
[3] Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA
[4] Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, Ken
[J]. CURRENT OPINION IN MICROBIOLOGY, 2011, 14 (05) : 550 - 555
[5] Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers
Crandon, Jared L.
Nicolau, David P.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 3299 - 3306
[6] Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
Ehmann, David E.
Jahic, Haris
Ross, Philip L.
Gu, Rong-Fang
Hu, Jun
Kern, Gunther
Walkup, Grant K.
Fisher, Stewart L.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (29) : 11663 - 11668
[7] In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
Endimiani, Andrea
Choudhary, Yuvraj
Bonomo, Robert A.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3599 - 3601
[8] Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
Lagace-Wiens, P. R. S.
Tailor, F.
Simner, P.
DeCorby, M.
Karlowsky, J. A.
Walkty, A.
Hoban, D. J.
Zhanel, G. G.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 2434 - 2437
[9] In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Levasseur, Premavathy
Girard, Anne-Marie
Claudon, Monique
Goossens, Herman
Black, Michael T.
Coleman, Kenneth
Miossec, Christine
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (03) : 1606 - 1608
[10] Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
Livermore, David M.
Mushtaq, Shazad
Warner, Marina
Zhang, Jiancheng
Maharjan, Sunil
Doumith, Michel
Woodford, Neil
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) : 390 - 394

← 1 2 →